VWM
CYTK icon

Vermillion Wealth Management’s Cytokinetics CYTK Stock Holding History

Vermillion Wealth Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-7
Closed -$461 – 1767
2026
Q1 		$461 Buy
+7
New +$445 ﹤0.01% 1045
2025
Q4 		– Sell
-10
Closed -$550 – 644
2025
Q3 		$550 Buy
+10
New +$412 ﹤0.01% 1475

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vermillion Wealth Management's CYTK Position: Q2 2026 in Review

Vermillion Wealth Management sold out of Cytokinetics (CYTK) in Q2 2026, closing a stake of 7 shares — an estimated $461 sold.

Vermillion Wealth Management first reported a position in CYTK in Q3 2025 and held it in 2 quarters. The position peaked at $550 in Q3 2025. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Vermillion Wealth Management reported no remaining Cytokinetics position as of Q2 2026 after selling out during the quarter.
  • Vermillion Wealth Management sold 7 Cytokinetics shares in Q2 2026, an estimated $461.
  • Vermillion Wealth Management first reported a position in Cytokinetics in Q3 2025 and held it in 2 quarters.
  • Vermillion Wealth Management's Cytokinetics position peaked at $550 in Q3 2025.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Vermillion Wealth Management's 13F filing for Q2 2026, filed 16 Jul 2026.